David Kobliska, MD
Family Medicine · Eugene, ORNPI 1386651560
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 206 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 206 payments — averaging $19.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$481
- Amgen$385
- AstraZeneca$352
- Pfizer$316
- Exact Sciences$309
- GSK$261
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,958100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $481 |
| Amgen | 19 | $385 |
| AstraZeneca | 17 | $352 |
| Pfizer | 19 | $316 |
| Exact Sciences | 13 | $309 |
| GSK | 13 | $261 |
| Novo Nordisk | 12 | $218 |
| Lilly USA, LLC | 12 | $215 |
| Otsuka America Pharmaceutical, Inc. | 10 | $181 |
| Bristol Myers Squibb | 9 | $179 |
| Boehringer Ingelheim | 6 | $149 |
| Organon | 3 | $106 |
| Novartis | 5 | $105 |
| Sanofi Pasteur Inc. | 5 | $100 |
| Bayer | 6 | $93 |
| Kowa Pharmaceuticals America, Inc. | 4 | $75 |
| Johnson & Johnson | 4 | $74 |
| Corcept Therapeutics | 3 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $53 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Dexcom, Inc. | 2 | $38 |
| Phathom Pharmaceuticals, Inc. | 2 | $33 |
| Viatris Specialty LLC | 1 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Vertex | 1 | $20 |
| Lundbeck LLC | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
How this compares
$3,974 in reported general payments places this provider in the 95th percentile of 1,221 family medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 179 | $181,278 |
| TrulicityDulaglutide | 118 | $139,476 |
| OzempicSemaglutide | 104 | $118,082 |
| JardianceEmpagliflozin | 69 | $78,286 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $59,705 |
| MounjaroTirzepatide | 44 | $50,331 |
| XareltoRivaroxaban | 25 | $38,304 |
| RexultiBrexpiprazole | 16 | $22,975 |
| FarxigaDapagliflozin Propanediol | 16 | $22,786 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $16,362 |
| Bydureon BciseExenatide Microspheres | 17 | $14,803 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $10,273 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $10,071 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,458 |
| DuleraMometasone/Formoterol | 25 | $8,402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $215 | $189,807162 claims |
| PfizerEliquis | $316 | $181,278179 claims |
| Novo NordiskOzempic | $218 | $118,082104 claims |
| Boehringer IngelheimJardiance | $149 | $78,28669 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $261 | $69,97888 claims |
| Johnson & JohnsonXarelto | $74 | $38,30425 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $352 | $37,43250 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $181 | $22,97516 claims |
| Sanofi-aventis U.S. LLCLantus | $14 | $2,60919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,221 family medicine providers in Oregon.
Other family medicine in Eugene
- Hylke SniederEugene$6K
- Randy ReeseEugene$5K
- Eden MillerBend$1.7M
- Anil RajaniHood River$325K
- Stephen NelsonMedford$101K
- Karen KahnAshland$86K
- Robert GobboPortland$53K
- Kevin MillerSisters$39K
- Morris MaizelsCentral Point$25K
- Maureen MaysPortland$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.